scholarly journals A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study

2008 ◽  
Vol 19 (5) ◽  
pp. 977-983 ◽  
Author(s):  
B.A. Burtness ◽  
J. Manola ◽  
R. Axelrod ◽  
A. Argiris ◽  
A.A. Forastiere
2017 ◽  
Vol 22 (7) ◽  
pp. 782 ◽  
Author(s):  
Marco Siano ◽  
Francesca Molinari ◽  
Vittoria Martin ◽  
Nicolas Mach ◽  
Martin Früh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document